Мексидол Drug photo

The description is actual on 04.09.2014

  • Latin name: Mexidolum
  • ATH code: N07XX
  • Active ingredient: Etilmetilgidroksipiridina succinate (Aethylmethylhydroxypyridini succinas)
  • Producer: FUGP "Armavir Biological Factory", LLC Meditsinsky Center Ellara, LLC NPK Farmasoft (Russia)


Succinate as active agent (50 mg on 1 ml) and auxiliary components is a part of drug in the form of solution for injections ethylmethylhydroxypyridine:

  • sodium metabisulphite;
  • water for injections.

Meksidol 125 mg of active ingredient (succinate ethylmethylhydroxypyridine), and also a number of auxiliary components are a part of one tablet:

  • lactoses monohydrate;
  • sodium carboxymethylcellulose (karmeloz of sodium);
  • magnesium stearate.

Each tablet is covered with the cover of white or cream-white color consisting from:

  • opadry the II white (macrogoal polyethyleneglycol);
  • polyvinyl alcohol;
  • talc;
  • titanium dioxide.

Release form

Drug Meksidol has two forms of release: in ampoules and in tablets.

Meksidol in ampoules is intended for infusions and intramuscular injections. Solution is issued in ampoules from colourless or svetozashchishchenny glass on which the point of a break is designated in the blue color or in the white color and three marking rings, upper of which yellow color, an average — white, lower — red.

Ampoules have the capacity of 2 or 5 ml and are packed on 5 pieces into blister strip packagings. Cardboard packaging is completed with 1 or 2 planimetric packagings, and also the instruction on a medical use of drug.

For hospitals of hospitals solution Meksidol is packed on 4, 10 or 20 blister strip packagings.

One tablet of drug Meksidol has the weight of 125 mg and is intended for intake. Tablets are issued packed on 10 pieces into blister strip packagings from PVC film and aluminum foil or on 90 pieces in the plastic banks made of food plastic.

For hospitals of medical institutions of a tablet are issued in the plastic banks made of food plastic on 450 or on 900 pieces in everyone.

The description of drug in the form of solution for injections

Meksidol in ampoules has an appearance of transparent liquid which can be both colourless, and slightly yellowish.

The description of the tableted Meksidol's form

Tablets are biconvex, a round form, are covered with a cover which color can vary from white to white with slightly cream shade.

Pharmacological action

Medicine Meksidol belongs to pharmacological group "The Means Influencing a Nervous System".

Drug is characterized:

  • antioxidant;
  • antihypoxemic;
  • membranostabiliziruyushchy;
  • nootropic;
  • anksiolitichesky properties.

Besides, it renders expressed a stress - protective action (that is increases resistance of an organism to a stress), promotes memory improvement, possesses ability to warn or stop attacks of spasms, and also reduces concentration of separate fractions of lipids (in particular, lipoproteins of low density) in various fabrics and liquids of an organism.

Pharmacodynamics and pharmacokinetics


Pharmacological properties of Meksidol are caused by activity of the succinate ethylmethylhydroxypyridine which is his part.

According to Wikipedia this substance belongs to the category of the medicines which are preventing or slowing down processes of peroxide oxidation of membrane lipids in cells.

Etilmetilgidroksipiridina succinate belongs to a class 3 of oxypyridines and is derivative pyridine of the general formula C5H4_nN (OH) n.

Substance has an appearance of colourless crystals which are characterized by ability with ease to be dissolved in ethanol and acetone, to be dissolved moderately in water and is limited — in diethyl ether, benzene and ligroin.

The mechanism of effect of ethylmethylhydroxypyridine of succinate is defined its antioxidant and membranoprotektorny by properties.

Working as antioxidant, it slows down and suppresses chain oxidizing reactions in which the active free radicals provided peroxide (RO2 *), alkoxyl (RO * take part) and alkyl (R *) oxygen forms.

Thanks to it against Meksidol's use:

  • activity of antioxidant enzyme of a superoxide scavenger (SOD) increases;
  • indicators of a ratio of proteins and lipids raise;
  • indicators of viscosity of cellular membranes decrease and, respectively, their flowability increases.

Drug regulates and normalizes indicators of activity of membrane-bound enzymes (in particular, the main enzyme of cholinergic system of acetylcholinesterase, class enzyme a LiAZ of adenylatecyclase and calcium - independent FDE (phosphodiesterase)), and also indicators of activity of receptor complexes (for example, the GAMK-benzodiazepinovykh complex of receptors).

As result:

  • at membranosvyazyvayushchy enzymes and receptor complexes ability to contact ligands increases;
  • normal indicators of the structurally functional organization of biological membranes are supported;
  • processes of transport of neuromediators are normalized;
  • indicators of synoptic transfer of neuromediators improve.

Tablets and Meksidol's pricks allow to increase body resistance to influence of various aggressive factors and morbid conditions connected with deficit of oxygen.

Drug effectively eliminates the symptoms caused by air hunger, a depressed case, ischemia, disturbances of blood circulation of a brain and also symptoms of systemic poisoning of an organism with medicines (in particular, means of antipsychotic action) or alcohol.

After a course of treatment Meksidol (intravenously, intramusculary or orally):

  • content of dopamine in a brain increases;
  • the course of metabolic processes in a brain is normalized;
  • brain blood supply is normalized;
  • microblood circulation improves;
  • rheological parameters of blood improve;
  • aggregation of thrombocytes decreases;
  • membranes of post-cellular structures of blood (erythrocytes and thrombocytes) at hemolysis are stabilized;
  • indicators of content of the general cholesterol decrease;
  • indicators of maintenance of LPNP decrease;
  • expressiveness of symptoms of a pankreatogenny toxaemia (systemic poisoning of blood) decreases;
  • expressiveness of a syndrome of the endogenous intoxication caused by acute pancreatitis decreases;
  • compensatory activity of aerobic glycolysis amplifies;
  • in anoxic conditions degree of inhibition of oxidizing processes in a cycle of tricarboxylic acids decreases (tricarbonic acid cycle);
  • content of adenosinetriphosphate (ATP) and creatine phosphoric acid (creatine phosphate) increases;
  • energy synthesis by cellular mitochondrions becomes more active;
  • cellular membranes are stabilized;
  • the course of processes of a metabolism in the myocardium sites affected with ischemia is normalized;
  • the area of a zone of a necrosis decreases;
  • electric activity of heart and its contractility is recovered and improves (at patients with cardiac dysfunction of reversible type);
  • the blood stream in the myocardium sites affected with ischemia increases;
  • expressiveness of effects of the reperfusion syndrome caused by acute coronary insufficiency decreases.

Treatment by drug Meksidol in/in or in oil allows to keep ganglionic cells, and also nerve fibrils of sensory cells of a mesh cover of an eye to patients with the progressing forms of the neuropathy caused by an ischemic disease and a hypoxia.

At the same time at patients essential increase of functional activity of a mesh cover of an eye and an optic nerve is noted, visual acuity increases.

The Antistressorny effect of treatment Meksidol is expressed by tablets in a look:

  • normalization of behavior after the postponed stress;
  • disappearances of symptoms of somatovegetativny frustration;
  • normalization of cycles of a dream and wakefulness;
  • recovery (partial or full) the broken abilities to training;
  • memory recovery;
  • reduction of expressiveness of dystrophic and morphological changes in various departments of a brain.

Also Meksidol is the means which is effectively eliminating symptoms which arise at abstinent states.

He removes displays of intoxication caused by alcoholic abstinence (as neurologic character, and neurotoxic), recovers behavioural disturbances, normalizes vegetative functions, removes or reduces expressiveness of disturbances of the cognitive functions provoked by long alcohol intake or sharp refusal of it.


After an intramuscular injection active ingredient of Meksidol is defined in a blood plasma on an extent of four hours. Time during which the maximum plasma concentration is reached makes from 0,45 to 0,5 hours.

Meksidol is quickly enough absorbed from a blood channel in various fabrics and bodies and also quickly brought from an organism: the average time of deduction of ethylmethylhydroxypyridine of succinate varies ranging from 0,7 till 1,3 o'clock.

Biotransformation of ethylmethylhydroxypyridine of succinate occurs in a liver. As a result of it phosphate-3-oxypyridine, a glucloss conjugates and other products of a metabolism are formed. And separate of them are characterized by pharmacological activity.

Drug is excreted mainly with urine and, generally in a glyukuronkonjyugirovanny form. Its insignificant quantity is output in not changed look.

According to the summary to Meksidol, reliable differences in pharmacokinetic profiles of ethylmethylhydroxypyridine of succinate at reception of a single dose and passing of course treatment are absent.

After oral administration of a tablet Meksidol of ethylmethylhydroxypyridine succinate is quickly absorbed, quickly distributed in various fabrics and bodies and quickly removed from an organism.

From 4,9 to 5,2 hours later after reception of a tablet its active agent is not found in a blood plasma of the patient any more.

After biotransformation in a liver by means of a konjyugirovaniye with glucuronic acid five metabolites are formed. In particular, phosphate-3-oxypyridine which then breaks up under the influence of an alkaline phosphatase to 3 oxypyridine and phosphoric acid.

Besides, in large numbers active agent which is defined in the patient's urine still 24-48 hours later after administration of drug, two glyukuronkonjyugat and substance which is removed from an organism in large numbers with urine is formed pharmacological.

Meksidol elimination half-life after intake varies ranging from 2 till 2,6 o'clock.

Substance is removed, mainly, with urine in the form of metabolites (especially intensively this process proceeds in the first four hours after reception) and only its insignificant part is excreted in not changed look.

Excretion indicators with drug urine in not changed look and in the form of products of a metabolism are characterized by individual variability.

Indications to Meksidol's use

Indications to use of pricks of Meksidol (intravenously or intramusculary):

  • acute disorders of blood circulation in a brain;
  • craniocereberal injuries (also injections of drug are appointed for removal or reduction of expressiveness of effects of craniocereberal injuries);
  • slowly progressing insufficiency of brain blood supply (distsirkulyatorny encephalopathy);
  • syndrome of neurocirculatory (vegeto-vascular) dystonia;
  • easy forms of frustration of the cognitive funktsiiaterosklerotichesky nature of an origin;
  • alarming frustration by which neurotic and neurosis-like (pseudo-neurotic) states are followed;
  • acute myocardial infarction (drug is appointed from the first days in the form of droppers or intramuscular injections as a part of a complex of therapeutic actions);
  • open angle glaucoma of primary type (Meksidol in ampoules is intended for treatment of a disease at various stages, complex therapy is considered the most effective at the same time);
  • the syndrome of alcoholic abstinence which is characterized by dominance of pseudo-neurotic and vegetovascular frustration;
  • organism intoxication symptoms means of antipsychotic action;
  • the pyoinflammatory processes proceeding in an acute form in the field of an abdominal cavity (including necrotic pancreatitis or peritonitis; drug is appointed as a part of a complex of therapeutic actions).

Indications to use of tablets Meksidol:

  • effects of acute disorders of blood circulation in a brain, including effects TIA (tranzitorny ischemic attack), and also as a prophylactic at a stage of a decompensation of the diseases caused by disturbance of cerebral circulation;
  • insignificant craniocereberal injuries and their effects;
  • noninflammatory diseases of a brain (encephalopathy) of various genesis (for example, distsirkulyatorny or posttraumatic);
  • alarming frustration by which neurotic and pseudo-neurotic states are followed;
  • ischemic disease (as a part of a complex of therapeutic actions);
  • the syndrome of alcoholic abstinence which is shown, mainly, in the form of pseudo-neurotic, vegetovascular and post-abstinent frustration;
  • symptoms of poisoning with antipsychotic drugs;
  • asthenic syndrome.

Also the indication to use of medicine in the tableted form is existence at the patient of the simpomokompleks caused by impact on an organism of stressorny factors.

Besides, in the preventive purposes Meksidol is shown to patients at whom the risk of development of somatopathies owing to influence of extreme factors and loadings is high.

The mechanism of action of Meksidol is caused by its antigipoksantny, antioxidant and membranoprotektorny properties. Therefore on the questions "From What Tablet Meksidol?" and "When Solution Meksidol Is Effective?", specialists answer that the most reasonable and successful purpose of drug is considered at:

  • craniocereberal injuries;
  • epilepsies;
  • spasms;
  • phobias and neurosises;
  • VSD;
  • sclerosis;
  • encephalopathies of various etiology, etc.

Contraindications on Meksidol

Contraindications to purpose of drug are:

  • hypersensitivity to ethylmethylhydroxypyridine to succinate or any of auxiliary components;
  • acute liver failure;
  • acute renal failure.

Side effects of Meksidol

Drug is characterized by good tolerance and quite seldom provokes these or those undesirable effects.

Side effects which in some cases can be noted after Meksidol's reception in the form of solution:

  • nausea attacks;
  • the increased dryness of a mucous membrane in an oral cavity;
  • the increased drowsiness;
  • allergy symptoms.

To side effects, potentially possible after reception of tablets Meksidol, carry:

  • Individual reactions of dispeptic character which are shown in the form of painful feelings or discomfort in a stomach, an eructation, nausea, heartburn, abdominal distention, feeling of a raspiraniye in a stomach, an unstable chair etc.
  • Individual reactions of dispepsichesky character which are expressed as a strong meteorism, rumbling in intestines, disorders of appetite, general weakness, slackness etc.
  • Individual allergic reactions.

Also drug sometimes raises or lowers arterial pressure, provokes emotional reactivity, a distal hyperhidrosis, lacks of coordination and process of backfilling.

Application instruction of Meksidol: way and dosage

Meksidol's pricks: application instruction. How to enter intramusculary and intravenously

Drug in the form of solution for injections is intended for introduction intramusculary or in a vein (method of jet or drop infusion). If Meksidol is appointed for intravenous administration, contents of an ampoule should be parted in isotonic solution of sodium chloride.

Jet infusion assumes administration of solution within five-seven minutes, in the drop way the drug is administered with a speed from forty to sixty thaws a minute. At the same time the most admissible dose should not exceed 1200 mg a day.

Before pricking intramusculary or to administer the drug intravenously, it is necessary to study the instruction. The optimum dosage of Meksidol in ampoules is selected individually in each case depending on the diagnosis of the patient and character of a course of his disease.

Meksidol's dosing in the form of solution

Acute disorders of blood circulation of a brain: from 200 to 500 mg in the drop way in a vein two-four times a day within 10-14 days.

Further the drug should be administered intramusculary. As it is specified in the instruction, such method of treatment is the most effective. Intramusculary solution is entered for two weeks, by two or once a day, in the dose equal from 200 to 250 mg.

Elimination of effects of craniocereberal injuries: the drug is administered in the drop way in the dose equal from 200 to 500 mg. Frequency rate of introductions — from 2 to 4, duration of a course of treatment — from 10 to 15 days.

Slowly progressing insufficiency of brain blood supply at a decompensation stage: the drug is administered by a drop or jet method of times or two in days within two weeks.

The dose is selected individually and varies ranging from 200 to 500 mg. Further treatment assumes purpose of intramuscular injections: during the next 14 days to the patient enter from 100 to 250 mg of Meksidol a day.

As a prophylactic from distsirkulyatorny encephalopathy: drug is appointed for introduction to a muscle, the daily dose makes from 400 to 500 mg, frequency rate of introductions — 2, duration of a therapeutic course — two weeks.

Easy disturbances of cognitive functions at patients of old age and alarming frustration: solution is entered into a muscle, the daily dose varies ranging from 100 to 300 mg, duration of a therapeutic course — from two weeks to one month.

Acute form of a myocardial infarction (in combination with other therapeutic actions): medicine is entered into a muscle or a vein for two weeks in combination with traditional measures which are taken for treatment of patients with a myocardial infarction.

In the first five days of a therapeutic course the drug is recommended to be administered intravenously by method of drop infusion, further it is possible to pass to intramuscular injections (injections continue to be given within nine days).

At an infusional method of introduction Meksidol part in isotonic solution of sodium chloride or in 5-tiprotsentny solution of glucose. The recommended volume — from 100 to 150 ml, time of infusion can vary ranging from half an hour till one and a half o'clock.

In cases, when necessary, administration of solution is allowed in the drop way (at the same time duration of infusion has to make not less than five minutes).

Both intravenously, and intramusculary the drug should be administered three times a day with an interval at eight o'clock. An optimum dose — from 6 to 9 mg a day on each kilogram of body weight of the patient. Respectively, the single dose makes 2 or 3 mg on kilogram of body weight.

At the same time the most admissible daily dose should not exceed 800 mg, and one-time — 250 mg.

Open angle glaucoma (for various stages of a disease in combination with other therapeutic actions): the drug is administered intramusculary for two weeks, the daily dose varies ranging from 100 to 300 mg, frequency rate of injections — from 1 to 3 during the day.

Alcoholic abstinence: the way of introduction — drop infusion or intramuscular injections, a daily dose varies ranging from 200 to 500 mg, frequency rate of injections — 2 or 3 in days. Duration of a therapeutic course — from 5 to 7 days.

Intoxication antipsychotic drugs: a way of introduction — intravenously, a daily dose — from 200 to 500 mg, duration of a therapeutic course — from one to two weeks.

Acute purulent inflammatory processes of an abdominal cavity: drug is shown to appointment both in the first days before an operative measure, and for the first days after the performed operation. A way of introduction — intravenously kapelno and intramusculary.

The dose is selected depending on severity and a form of a disease, extensiveness of defeat, features of a clinical picture. It varies ranging from 300 (at an easy form of necrotic pancreatitis) to 800 mg (in case of extremely severe disease) in days.

Drug withdrawal has to be carried out gradually and only on reaching steady positive clinical laboratory effect.

Tablets Meksidol: application instruction

Tablets Meksidol are intended for oral administration. The daily dose varies ranging from 375 to 750 mg, frequency rate of receptions — 3 (one-two tablets three times a day). The most admissible dose — 800 mg a day that corresponds to 6 tablets.

Duration of a course of treatment depends on a disease and reaction of an organism of the patient to the appointed treatment. As a rule, it makes from two weeks to one and a half months. In a case when drug is appointed for stopping of symptoms of alcoholic abstinence, duration of a course makes from five to seven days.

At the same time sharp drug withdrawal is inadmissible: treatment is stopped gradually, reducing a dose within two-three days.

At the beginning of a course to the patient appoint to take one or two tablets for reception of times or twice a day. The dose is gradually raised to receiving positive clinical effect (at the same time it should not exceed 6 tablets a day).

"Ischemic disease" makes duration of a therapeutic course at patients with the diagnosis from one and a half to two months. If necessary the repeated course can be on doctor's orders appointed. Optimum time for purpose of a repeated course — fall and spring.


The instruction warns that such medicine as Meksidol, in case of exceeding of the recommended dose can provoke drowsiness development.


Drug is compatible to all medicines which are used for treatment of somatopathies.

At the simultaneous use with benzodiazepine derivatives, antidepressive, antipsychotic, tranquilizing, anticonvulsant (for example, carbamazepine) and protivoparkinsonichesky (levodopa) drugs strengthens their action on an organism.

It allows to reduce significantly doses of the last, and also to reduce probability of development and expressiveness of undesirable side effects (for what appoint Meksidol to separate categories of patients).

Drug reduces expressiveness of toxic effects of ethanol.


Meksidol and Piracetam: compatibility

Piracetam as active component is a part of the drug Nootropil which is applied to improvement of cognitive (cognitive) processes of a brain.

Joint purpose of Nootropil and Meksidol allows to achieve the best results in increase of mental capacities at children, recovery of patients after the postponed ischemic stroke or a coma, treatment of an alcoholism, psychoorganic syndrome (including at patients of old age with reduced memory, lability of mood, behavioural frustration) etc.

It should be noted, however, that contrary to nootropic drugs (and, in particular, Nootropil) Meksidol has no the activating effect on an organism, does not provoke sleep disorders and increase of convulsive activity.

On the therapeutic effectiveness it considerably exceeds Piracetam.


Meksidol's compatibility and Actovegin

Meksidol and Actovegin possess the similar mechanism of action therefore quite often they are appointed in a combination with each other. However, as Actovegin is made from veal blood, it a little more often than Meksidol, provokes these or those side effects.

Actovegin at molecular level accelerates processes of utilization of oxygen and glucose, increasing thereby resistance of an organism to conditions of a hypoxia and promoting increase of a power metabolism.

Being powerful anti-hypoxanthomas, Actovegin is appointed at a diabetes mellitus, craniocereberal injuries, after a stroke, at a sclerosis, cerebral insufficiency, disturbances of peripheric and venous circulation, etc.


Compatibility of Cavintonum and Meksidol

As active component of Cavintonum the Vinpocetine which synthesize from Vincaminum — alkaloid of a perennial plant a periwinkle small is used. Substance possesses ability to expand vessels, to improve blood circulation of a brain, renders the expressed anti-aggregation and anti-hypoxemic effect.

Besides, the Vinpocetine is capable to influence the processes of a metabolism proceeding in brain tissues and reduces aggregation (or, otherwise, adhesion) thrombocytes, improving that its rheological properties.

Terms of sale

Drug belongs to the category released according to the recipe of the doctor.

Storage conditions

It is necessary to store Meksidol in dry, protected from light and the place, unavailable to children, at a temperature no more than 25 °C.

Period of validity

Tablets and solution Meksidol are suitable for use within 3 years. After the term specified on packaging it is forbidden to apply them.

Special instructions

Solution for intramuscular and intravenous administration

At the patients having predisposition to allergic reactions at hypersensitivity to sulfites, and also at the people sick with bronchial asthma, against treatment heavy reactions of hypersensitivity can develop.

Tablets Meksidol

During a course of treatment tablets Meksidol it is necessary to observe extra care at management of transport and the performance interfaced to health hazard and lives of works. It is connected with the fact that drug possesses ability to slow down the speed of psychomotor reactions and to reduce concentration of attention.

Meksidol's analogs

Many patients quite often have a question "What It Is Possible to Replace the Drug Appointed by the Doctor with and whether There Are Analogues cheaper?".

Meksidol's analogs in tablets:

  • tablets and capsules Gipoksen;
  • film coated tablets of Maxey B6;
  • homeopathic drops for oral administration of Memoriya;
  • Nukleo's capsules tsmf forte;
  • tablets Tserebronorm;
  • tablets in a kishechnorastvorimy cover Tsitoflavin;
  • tablets Glycine;
  • film coated tablets Polineurinum.

Analogs of drug in ampoules are:

  • solution for intramuscular introduction of Vitagamm;
  • solution for intravenous administration Gipoksen;
  • solution for intramuscular introduction Kombilipen;
  • solution for intramuscular introduction Kompligam In;
  • lyophilisate for solution for injections Korteksin;
  • homeopathic solution for intramuscular introduction the Placenta a compositum;
  • solution for intramuscular introduction of Trigamm;
  • solution for intravenous administration Tsitoflavin;
  • solution for infusional introduction Emoksibel;
  • solution for intravenous and intramuscular administration Etoksidol.

Quite often patients have a question: what of analogs is better, cheaper than the drug prescribed them where there are less side effects, etc. Therefore it should be taken into account this subject in details.


What it is better — Actovegin or Meksidol?

Drugs are used in the similar field of medicine. For this reason for achievement of more expressed clinical effect for patients they are appointed it is combined.

Meksidol and Actovegin is not recommended to mix in one syringe because their active components can enter interaction, breaking at the same time structure of each other and increasing probability of development of side reactions.


What it is better — Cavintonum or Meksidol?

Both Cavintonum, and Meksidol are complementary drugs therefore they are often appointed in a complex for elimination of effects of disturbance of blood circulation in a brain.

The main requirement at the same time — drugs should not mix up in one dropper or in one syringe.


What it is better — Meksidol or Meksikor?

Meksikor is generic (synonym) of Meksidol. Therefore drug is used in the same field of medicine, as Meksidol. It is issued in the form of gelatinous capsules, tablets and solution for injections.

Meksikor effectively removes uneasiness, relieves of fears and improves mood, improves memory, attention, increases working capacity and abilities to training, eliminates intoxication symptoms with alcohol and reduces pathological effects of the had stroke.

Drug belongs to group of metabolic cardiocytoprotectors. The mechanism of its action is caused by merge in its structure of an antigipoksant of succinate and antioxidant of an emoksipin which is characterized by a broad spectrum of activity.

In combination with other therapeutic actions Meksikor is shown for treatment of ischemia of a myocardium and an ischemic stroke. Also it is recommended to appoint it in therapy of lungs and moderately expressed cognitive frustration and for for reduction of expressiveness of symptoms of distsirkulyatorny encephalopathy.


Meksiprim and Meksidol — what is better?

Meksiprim is the German analog of Meksidol. His producer is the STADA Arzneimittel AG concern. The main difference of drugs — structure of auxiliary components of a kernel and cover of tablets. The mechanism of action and the indication to use for them are similar.
Meksidol or Mildronate — what is better?

Mildronate belongs to group of the drugs improving a metabolism and power supply of fabrics. It is issued in the form of gelatinous capsules, solution for injections and syrup for intake.

Active ingredient of drug — meldoniya (a trimetilgidraziniya propionate) which on the structure is similar to a gamma butyrobetaine (the substance which is present at each cell of a live organism).

Mildronate is used as a vasodilator. Besides, drug improves supply of bodies and fabrics with oxygen, promotes increase of humoral and fabric immunity, reduces indicators of arterial pressure.

Meksidol and Mildronate according to the decision of the doctor can be appointed as a part of a combination therapy for treatment of patients with:

  • effects of an alcoholic abstinence syndrome;
  • disturbances of blood circulation in a brain;
  • ischemic disease.


  • Meksidol tent Professional White 65gmeksidol toothpaste of Dent
  • Meksidol of 5% 5 ml No. 20 of an ampulyellar of MTs
  • Meksidol of 5% 2 ml No. 10 of an ampulyellar of MTs
  • Meksidol of 5% 2 ml No. 50 of an ampulyellar of MTs
  • Meksidol of 125 mg No. 30 of a tablet

Drugstore of IFC

  • Meksidol tbl p / about 125 mg No. 50 **, ZIO-Zdorovye Zaorossiya
  • Meksidol tent of a zubn.past of 65 g Complex, Farmasoft Bidding. Computer. Ooorossiya
  • Meksidol solution for in 5% 5 ml of amp No. 5 *, Farmasoft of NPK of Ltd company/Ellar MTS Ooorossiya
  • Meksidol solution for in 5% 2 ml of amp No. 10, Ellara of LLC Mtsrossiya
  • Meksidol tent opolask.d / oral cavities of 250 ml of Farmasoft Bidding. Computer. Ooorossiya
to show still


  • Meksidol50
  • Meksidol30


  • Meksidol tab 125 mg No. 30


  • Meksidol of 50 mg/ml 5 ml No. 5 solution d/in.v/v.v/m.amp. Ellara MTs of Ltd company (Russia)
  • Meksidol of 125 mg No. 50 tabl.p.o. Health ZIO firm of closed joint stock company (Russia)
  • Meksidol of 50 mg/ml 5 ml No. 5 solution d/in.v/v.v/m.amp. Armavir biological factory (Russia)
  • Meksidol of 50 mg/ml 2 ml No. 10 solution d/in.v/v.v/m.amp. Armavir biological factory (Russia)
  • Meksidol of 5%/2 ml No. 10 solution for in.amp. Ellara MTs of Ltd company (Russia)
to show still
Section: For a nervous system
PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Meksidol surely consult with the attending physician.